Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | May 21, 2026 | May 22, 2026 |
| Rallybio CorpRLYB · Entity 6838 | Director | May 13, 2025 | May 15, 2025 |
| uniQure N.V.QURE · Entity 4162 | Director | June 13, 2024 | June 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.63 · Expires 2036-05-21 | Direct | 6,090 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 6,090 · Balance 6,090 F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Rallybio Corp
Report date May 13, 2025 · Filed May 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2035-05-13 | Direct | 28,500 |
Reported balance
After 2025-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-13 · Grant · Acquired 28,500 · Balance 28,500 F1: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.
uniQure N.V.
Report date June 13, 2024 · Filed June 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,203 |
Reported balance
After 2024-06-13 transaction · row 1
1 source rowRow 1 · 2024-06-13 · Sale · Disposed 2,220 · Balance 20,203 F1: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date September 26, 2019 · Filed September 30, 2019
Section 16 reporting ended · disclosed 2019-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 678,149 |
Ending reported balance
After 2019-09-26 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2019-09-26 · Exercise / conversion · Acquired 1,711,079 · Balance 1,711,079 Row 2 · 2019-09-26 · Tax withholding · Disposed 1,113,492 · Balance 597,587 Row 3 · 2019-09-26 · Exercise / conversion · Acquired 145,303 · Balance 742,890 Row 4 · 2019-09-26 · Tax withholding · Disposed 95,156 · Balance 647,734 Row 5 · 2019-09-26 · Exercise / conversion · Acquired 205,479 · Balance 853,213 Row 6 · 2019-09-26 · Tax withholding · Disposed 175,064 · Balance 678,149 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2025-12-15 | Direct | 0 |
Reported balance
After 2019-09-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-09-26 · Exercise / conversion · Disposed 1,711,079 · Balance 0 F1: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2026-02-16 | Direct | 13,209 |
Reported balance
After 2019-09-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-09-26 · Exercise / conversion · Disposed 145,303 · Balance 13,209 F2: The shares vest as follows: 1/4th of the shares vest one year after January 4, 2016;1/48th of the shares vest monthly thereafter over the next three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-06-04 | Direct | 102,740 |
Reported balance
After 2019-09-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-09-26 · Exercise / conversion · Disposed 205,479 · Balance 102,740 F3: The shares vest as follows: 1/4th of the shares vest one year after January 3, 2017;1/48th of the shares vest monthly thereafter over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years.
F2: The shares vest as follows: 1/4th of the shares vest one year after January 4, 2016;1/48th of the shares vest monthly thereafter over the next three years.
F3: The shares vest as follows: 1/4th of the shares vest one year after January 3, 2017;1/48th of the shares vest monthly thereafter over the next three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2019 Filed Dec 17, 2019 21:06 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,000 | $70.50 | $141,000.00 |
DisclosureSEC source: 0000904454-19-000749 · edgar.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,352 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.50 to $70.51. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:06 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 2,000 | $5.37 | $10,740.00 |
DisclosureSEC source: 0000904454-19-000749 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 09, 2019 Filed Dec 9, 2019 23:30 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,500 | $67.50 | $168,750.00 |
DisclosureSEC source: 0000904454-19-000737 · edgar.xml · nonDerivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,352 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 23:30 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 7,382 | $64.39 | $475,326.98 |
DisclosureSEC source: 0000904454-19-000737 · edgar.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,852 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.32 to $64.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 23:30 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,700 | $63.69 | $108,273.00 |
DisclosureSEC source: 0000904454-19-000737 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,234 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.20 to $64.03. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionStock Option (right to buy) · Derivative | 205,479 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · derivative · entry 9 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,740 Underlying: Common Stock · 205,479 shares Expires 2027-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 3, 2017;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionStock Option (right to buy) · Derivative | 145,303 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · derivative · entry 8 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,209 Underlying: Common Stock · 145,303 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 4, 2016;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionStock Option (right to buy) · Derivative | 1,711,079 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · derivative · entry 7 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,711,079 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Tax withholdingCommon Stock | 175,064 | $16.64 | $2,913,064.96 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · nonDerivative · entry 6 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,149 Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionCommon Stock | 205,479 | $12.21 | $2,508,898.59 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · nonDerivative · entry 5 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Tax withholdingCommon Stock | 95,156 | $16.64 | $1,583,395.84 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · nonDerivative · entry 4 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,734 Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionCommon Stock | 145,303 | $6.48 | $941,563.44 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · nonDerivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Tax withholdingCommon Stock | 1,113,492 | $16.64 | $18,528,506.88 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,587 Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 21:52 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionCommon Stock | 1,711,079 | $6.48 | $11,087,791.92 |
DisclosureSEC source: 0001209191-19-051139 · doc4.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,711,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionStock Option (right to buy) · Derivative | 1,787 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001209191-19-024175 · doc4.xml · derivative · entry 6 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,711,079 Underlying: Common Stock · 1,787 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | SaleCommon Stock | 1,787 | $32.17 | $57,480.28 |
DisclosureSEC source: 0001209191-19-024175 · doc4.xml · nonDerivative · entry 4 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $32.1658, and the range of prices were between $32.11 and $32.20. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionCommon Stock | 1,787 | $6.48 | $11,579.76 |
DisclosureSEC source: 0001209191-19-024175 · doc4.xml · nonDerivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001209191-19-024175 · doc4.xml · derivative · entry 5 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,712,866 Underlying: Common Stock · 30,000 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | SaleCommon Stock | 30,000 | $32.11 | $963,300.00 |
DisclosureSEC source: 0001209191-19-024175 · doc4.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionCommon Stock | 30,000 | $6.48 | $194,400.00 |
DisclosureSEC source: 0001209191-19-024175 · doc4.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:20 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionStock Option (right to buy) · Derivative | 18,386 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001209191-19-017835 · doc4.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,742,866 Underlying: Common Stock · 18,386 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:20 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | SaleCommon Stock | 18,386 | $32.14 | $590,856.17 |
DisclosureSEC source: 0001209191-19-017835 · doc4.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $32.1362, and the range of prices were between $32.11 and $32.50. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:20 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Exercise / conversionCommon Stock | 18,386 | $6.48 | $119,141.28 |
DisclosureSEC source: 0001209191-19-017835 · doc4.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 22:28 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,210 | $31.32 | $37,897.20 |
DisclosureSEC source: 0000904454-19-000132 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,934 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $31.46. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2019 Filed Jan 30, 2019 01:37 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 5,295 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0000904454-19-000111 · edgar.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,295 Underlying: Ordinary Shares · 5,295 shares Expires 2029-01-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 25, 2019 Filed Jan 30, 2019 01:37 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000111 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,144 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:32 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 296,000 | $0.00 Strike: $30.73 | $0.00 |
DisclosureSEC source: 0001209191-19-002143 · doc4.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,000 Underlying: Common Stock · 296,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 2, 2019; 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 15:51 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,878 | $18.53 | $53,329.34 |
DisclosureSEC source: 0000904454-18-000095 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,914 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.41 to $18.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 15:46 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 6,390 | $0.00 Strike: $19.39 | $0.00 |
DisclosureSEC source: 0000904454-18-000064 · edgar.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,390 Underlying: Ordinary Shares · 6,390 shares Expires 2028-01-26 F3 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 15:46 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000064 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,792 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. F2 · balance_after: Includes (i) 5,000 restricted share units that vested in full on January 27, 2017 previously disclosed by the Reporting Person in Table II and (ii) 11,000 restricted share units that vested in full on January 27, 2018 previously disclosed by the Reporting Person in Table II. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:02 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $17.38 | $0.00 |
DisclosureSEC source: 0001209191-18-002240 · doc4.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-01-01 F1 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after January 2, 2018; 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:03 UTC | uniQure N.V. QURE · Entity 4162 | GrantRestricted Stock Units · Derivative | 11,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-003704 · doc1.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 11,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Unit vests 100% on January 27, 2018. F3 · derivative.expiration_date: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:03 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001140361-17-003704 · doc1.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 11,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The Stock Option vests 100% on January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.